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POLICY
International Charter of principles for sharing
bio-specimens and data
Deborah Mascalzoni*,1,2, Edward S Dove3, Yaffa Rubinstein4, Hugh JS Dawkins5,6,7,8, Anna Kole9,
Pauline McCormack10, Simon Woods10, Olaf Riess11, Franz Schaefer12,13, Hanns Lochmüller10,
Bartha M Knoppers3 and Mats Hansson1
There is a growing international agreement on the need to provide greater access to research data and bio-specimen collections
to optimize their long-term value and exploit their potential for health discovery and validation. This is especially evident for rare
disease research. Currently, the rising value of data and bio-specimen collections does not correspond with an equal increase in
data/sample-sharing and data/sample access. Contradictory legal and ethical frameworks across national borders are obstacles to
effective sharing: more specifically, the absence of an integrated model proves to be a major logistical obstruction. The Charter
intends to amend the obstacle by providing both the ethical foundations on which data sharing should be based, as well as
a general Material and Data Transfer Agreement (MTA/DTA). This Charter is the result of a careful negotiation of different
stakeholders' interest and is built on earlier consensus documents and position statements, which provided the general
international legal framework. Further to this, the Charter provides tools that may help accelerate sharing. The Charter has been
formulated to serve as an enabling tool for effective and transparent data and bio-specimen sharing and the general MTA/DTA
constitutes a mechanism to ensure uniformity of access across projects and countries, and may be regarded as a consistent
basic agreement for addressing data and material sharing globally. The Charter is forward looking in terms of emerging issues
from the perspective of a multi-stakeholder group, and where possible, provides strategies that may address these issues.
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INTRODUCTION TO THE INTERNATIONAL CHARTER OF
PRINCIPLES FOR SHARING BIO-SPECIMENS AND DATA
Sharing data and bio-specimens is essential for the discovery, new
knowledge creation and translation of various biomedical research
findings into improved diagnostics, biomarkers, treatment develop-
ment, patient care, health service planning and general population
health. The growing international agreement on the need to provide
access to research data sets to optimize their use and fully exploit their
long-term value has been articulated in many documents, including
the OECD Principles and Guidelines for Access to Research Data from
Public Funding, the Toronto Statement, and more recently the Global
Alliance for Genomics and Health’s White Paper.1–3 Contempora-
neously, the ambitious aims set out in the International Rare Disease
(RD) Research Consortium (IRDiRC.org), which seeks to develop 200
therapies and to diagnose most RDs by 2020, and the decision of the
European Commission asking all members states to develop a national
plan for RDs,4 provide further impetus. Although sharing of data and
samples is thought to be beneficial for most health-related research, it
is of highest importance for RD research because of the scarcity of
research participants, samples, data, resources and researchers for any
given RD.
Ideally, data and bio-specimens should be made widely
available to the most inclusive and ethically responsible research
community, but there is often resistance by institutions and
individuals who fear that they will not receive recognition for
their investment in building collections. Real and perceived risks of
discrimination of vulnerable patients groups because of health-
related data sharing also exist and must be considered in any
legislation or guidelines. Collecting data and storing biological
samples in accordance with ethical and scientific standards
requires intellectual, institutional and economic resources and,
critically, the participation of patients and the wider community
including otherwise healthy volunteers.
All data and material sharing agreements should be ethically robust
and mindful of the responsibilities owed to the donors to make best
ethical use of the samples and data consistent with their consent.
Researchers face very different requirements for data and sample
sharing. Data Transfer Agreement (DTA) and Material Transfer
Agreement (MTA) are often written in legal terms, and so are not
easily understood by scientists or institute administration officers who
serve as a conduit for these agreements. Hence the need to provide
a simplified overview of basic principles and a practical template
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(the MTA/DTA). The principles are equally valid and applicable for
Access Agreements (AAs).
The Charter, together with the template for general MTA/DTA,
constitutes an enabling tool to improve the governance and audit of
sharing data and specimens across multiple international settings. It is
written in simplified language to make it accessible and usable by
scientists and other stakeholders, and provides a consistent set of
principles that will improve interoperability nationally and
internationally.
The Charter has been developed to provide a common overview
and foundational framework of the practice of sharing, and to frame a
minimum list of the terms needed to achieve an equitable and ethically
grounded data sharing agreement through multi-stakeholder engage-
ment and consensus, including patient representatives, clinicians,
researchers, institutions and government agencies. This Charter is
the result of a careful negotiation of different stakeholder’s interest:
that includes a stakeholders workshop held in Brussels in October
2013. During the 2-day workshop, RD patient representatives, legal
experts, ethical experts, industry representatives and scientists debated
the issues and produced consensus positions that informed the
Charter. The model is the result of further analysis and is built on
earlier consensus documents and position statements, which provided
the P3G general legal framework and generic MTA.5 The Charter has
then been considered by the RD Connect Patient Ethics Council and
RD Connect Patient Advisory Council, which endorsed the Draft
Charter as the patient consulting bodies of RD Connect.
The MTA/DTA provides a clear and simplified template that can be
applied to different research contexts. It follows the Charter’s
principles and incorporates them in a mutual template agreement
between researchers (or institutions) that comprise best practices and
values. Ideally, both the provider and recipient should not only fulfil
legal requirements but also comply with ethical and quality assurance
mechanism recommendations to achieve the highest ethical standards.
Therefore, the suggested items constitute a best practice guideline.
The following five principles6 for the custodianship of bio-specimen
repositories and data, constitute the common premise for the Charter:
 Respect for privacy and autonomy: custodianship implies protection
of participants’ privacy. Privacy protection measures should be in
place and informed consent must provide provisions for future as
yet unspecified research using data and bio-specimens.
 Reciprocity: custodianship also implies giving back. Feedback of
general results should be channelled to institutions and patients.
 Freedom of scientific enquiry: custodianship should encourage
openness of scientific enquiry, and should maximize data and
bio-specimen use and sharing so as to exploit their full potential to
promote health.
 Attribution: the intellectual investment of investigators involved in
the creation of data registries and bio-repositories is often sub-
stantial, and could be acknowledged by mutual agreement.
 Respect for intellectual property: the sharing of data and bio-
specimens needs to protect proprietary information and address the
requirements of institutions and third-party funders.
As described by Knoppers et al,7 the sharing of personal data is a
form of data processing, in accordance with the EU directive 95/46/EC
on personal data protection. The processing of personal data requires
authorization from a data protection authority or an ethics review
board, unless directly permitted by law. Health-related personal data
are classified as sensitive, implying that confidentiality laws apply and
that processing requires consent from the data subject or permission
by law (on consent, see below). Different types of data are associated
with different degrees of intellectual investment by the researchers,
which should be reflected in sharing agreements. The sharing and
integration of data across research groups and national borders implies
that data (and metadata) must be sufficiently equivalent. As suggested
by the DataSHaPER platform for harmonizing data collection in
epidemiological research, the level of equivalence with regard to
primary information collected (eg, serum cholesterol level) and
qualifying factors that may affect the interpretation of data (eg,
whether the subject had been fasting before measurement) is likely
to be context- or consortium specific.8 Issues about the quality of data
accordingly have to be separately addressed by each party before
sharing and being described in an MTA/DTA.
Wherever possible, the complete anonymization of data and
bio-specimens should be avoided, based on the principle that this
would make it impossible to add relevant data as science progresses,
and precludes re-contacting donors and data subjects to communicate
future medical discoveries that may benefit them.9 This also reflects
RD patients’ views on the need to optimize data value in order to seek
results for patients and for the benefit of the broader community.
Similar considerations and issues concerning the anonymization of
data in large cohort population databases and biobanks have been
expressed more recently, and form an integral part of the consensus
being developed internationally;10,11 for a discussion, see also.12–15
Donors of bio-specimens and data should therefore be informed that
confidentiality will be taken seriously with the help of strict coding
measures, as described below, but that there is no guarantee of
complete anonymity because of the nature of the research and
advances in technology.
At the time of the collection of data and bio-specimens, their future
specific use may be difficult to anticipate or may only be described in
very broad general terms, for example, for cancer research, RD
research or medical research. The question about the acceptability
of broad consent16,17 has been deeply debated in the ethics and
legal literature,13–15,18–20 and there is some consensus on its
acceptability21,22 provided proper on-going ethical and legal oversight
are in place (approval by ethics review boards for every single project
is mandatory).
The need to re-contact and involve patients in research though, may
also lead to the development of patient centric approaches to consent
that provide a dynamic interaction. A number of patient centric
consent strategies exploiting online technologies have been developed
to help address the limits of a pure broad consent approach. Obviously
longitudinal population projects are in constant contact with their
participants but dynamic consent models14,15,22 offer an alternative
way to overcome the tension between broad and specific consent also
in non-longitudinal research such as clinical trials, by ensuring on-
going information and participant involvement after general consent
has been provided at the time of bio-specimens collection. Different
research platforms and legal frameworks may require more detailed
consent, but for the sharing procedures related to prospective
sampling and data acquisition we propose and outline a minimal
requirement strategy. Therefore, we further propose that templates for
informed consent in research projects of an epidemiological character
can be accepted if based on the notion of broadly described purposes
for future research, provided this is subject to ethics approval and
supported by a policy of regular updates to donors and a clear option
to withdraw. In fact, even when the purpose is described only in
general or broad terms, information regarding the process of research
may be specific on the relevant issues, for example, that the research
project implies the sharing of data across research groups and national
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borders, that complementary information may be added through
linkage to different registries’ medical records, that it involves genetic
analyses and collaboration with both academic and commercial
partners, whether or not there is any provision for return of research
findings, etc. So to overcome the lack of detailed research information
at the time of consent, we suggest an integrated approach entailing
broad consent coupled with provision of on-going information about
the general development of project, for instance by proper commu-
nication with the participants/donors through email, phone, a news-
letter, patient organizations contacts and regular website updates
dedicated to them.22
A sizeable number of samples currently exist in clinical biobanks as
well as patient data registries for which there is little or no expressed
consent for research, data/material sharing to other groups especially
industry, or where the scope of the consent may be unclear. These
samples may have been collected at a time when research ethics had
not been developed to the standard they are now. In RD, there may
not be an opportunity to obtain an equivalent sample or data set for
research. Rules and recommendations regarding information and
consent procedures need to take into account the complexity of
patient perceptions as well as the different characteristics of different
cohorts and collections.23,24
In order for researchers to be able to share samples and data of this
kind, a common framework of how to manage informed consent
concerns is needed. Legal frameworks may differ between countries
making it possible in some countries to use archived samples and data
without explicit consent, while researchers in other countries are
obliged to obtain new consent. However, this does not necessarily
constitute an obstacle for sharing across borders as each institution
needs only to adhere to their national legal requirements on the
information and consent procedures in order to satisfy the ethical
requirements necessary to send samples and data abroad.25,26
A recipient in another country can then use them either in a joint
venture together with the sender or for MTA regulated projects, even
if sampling and acquisition of data is differently regulated in that
country, provided the objectives of the research are the same.
Approval of these single projects by an ethics review board is always
required.
Respect for autonomy, in the sense of having a direct say on how
one’s samples and data will be used in some cases may involve
re-consent where according to the ethics committee the scope of the
original consent may preclude the suggested research use. This is
particularly relevant where the development of new techniques could
not have been anticipated when the samples were first collected.
Although ethics review is always requested for every single project, a
general requirement to obtain new informed consent in all cases may
be impractical and would also involve a potential for selection bias
because of drop outs, decreasing the scientific value of the data and the
sample collection.27,28 The potential psychological impact on the
research participants of re-contacting and re-consenting should be
considered, although neglecting to inform patients on this basis should
never be the default position and should be carefully evaluated in
order to avoid paternalistic approaches.14 RD research may be
particularly vulnerable to selection bias because the number of
available samples and data are intrinsically low for each condition,
ultimately jeopardizing research, which is in the interests of all parties.
However, careful consideration of the time, effort and other resources
required to adequately re-consent patients should be given, as low
numbers of patient research participants may also result in benefits of
re-consent with low drop-out rates. The actual balance and trade-off
between respect for autonomy and optimizing provision of new
treatment opportunities should be sensitive to and recognize the
needs of the RD community and the wider public.
Where legal provisions requiring informed consent were in place at
the time of sample/data collection, re-consent or notification with an
opt-out option, should be pursued. A clear distinction should be made
between collections in which a previous consent was obtained and
where a question was not asked, and one where a patient actively
declined an option or in which the information provided excluded
some options (eg, ‘your data will not be shared with any commercial
organizations’). In these instances, re-consenting or notification with
opt-out should be also pursued. For some older cohorts, the
researcher may still find re-consent achievable within reasonable
efforts, using this also as an opportunity to update or collect new
data. Other projects may be particularly vulnerable to drop outs and
one may want to use a scheme with notification and opt-out, thus still
respecting the autonomy of participants.
Where it is determined that re-contacting patients is unfeasible or
when inclusion of small sample numbers from across a large number
of collections and registries are of outmost importance or when
samples are held in older collections, an acceptable option could be a
waiver on re-consent. This option is not feasible in every legal system
and requires an adequate assessment of the reasons for asking for a
waiver to the ethics review board. Optional re-consent as well as
notification with an opt-out clause or general waiver of re-consent for
specific cases may create some efficiencies and still maintain ethically
responsible and practical ways to access samples an data spread across
many sites globally. Where a waiver for re-consent is required, a
careful explanation of the reasons that lead to this solution should be
provided to the ethics review board. The permission by the ethics
board to use the samples should specifically state the permission to
share abroad and foresee genetic analysis where appropriate. The
sharing of data and bio-specimens without consent needs to be
compliant with the appropriate legal framework.
In the case of bio-specimens and data from minors or collected
when the person was a minor, re-consent or notification with opt-out
clause should be always pursued. Data and bio-specimens from
deceased persons should be anonymized and used with ethics
approval. Some legal systems may impose specific restrictions (eg,
UK’s Human Tissue Act 2004).
Institutions and organizations may have legitimate proprietary
interests associated with data collected by researchers.9 Biobank
research infrastructures and data collections require investments and
intense labour, and therefore a legitimate institutional interest based
on the need to protect local investments exists. There is also another
layer of institutional interest: the integrity of a research endeavour that
has collected data based on original and promising hypotheses.29–31
The effective dissemination of research results is thus associated with
established criteria for acknowledging intellectual contributions and
originality through rules of authorship and intellectual property rights.
Custodianship implies the duty of recognizing the role of research
institutions and their legal and ethical duties to participants and
patients. There is agreement that general aggregated research results
should be either on open access databases or at least disseminated to
institutions and patients.
With regard to biobanks where the amount of samples may be
limited, it is recommended that the samples are used only for studies
reviewed by a competent and well-balanced data access committee so
as to ensure good scientific quality. This is motivated primarily by
ethical concerns for the protection of patient interests of reaping the
fruits of their donated samples in terms of truly improved diagnosis
and treatment opportunities. Data collections do not face scarcity but
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clinical quality registries are dependent on the trust of patients and
therefore good communication processes are required to maintain this
trust. Also, the submission of new data and reports using clinical
registries that are of low scientific quality may jeopardize the trust and
willingness of patients to consent and to continuously contribution
data. To this end, caretakers of the clinical registry should also be
granted a right to assess the quality of an application to acquire data
for a study, as a parallel to an intellectual property right, because they
have invested both personal intellectual and institutional resources in
order to create the registry. They should be the rightful protectors of
the integrity of the clinical registry in this sense. In practice, most
networks of bio- and data repositories do have some kind of scientific
evaluation committee to make these kinds of decisions, and we believe
for good reason. The protocols of investigators who request access to
clinical registries or biobanks should be vetted by a representative data
access committee for scientific quality and the bona fides of applicants
should also be authenticated, for example, through checking on their
background and institution affiliation with the institution or university
signing the MTA/DTA as co-responsible for the scientific integrity of
the applicant.
The Charter briefly outlines the guiding principles for data and
bio-specimen sharing together with the MTA/DTA that encloses these
ethical principles in a template model. The Charter, developed within
the framework of international research consortia projects, aims to
provide a tool to be used for effective, ethically grounded sharing in
the international context.
CHARTER OF PRINCIPLES FOR SHARING DATA AND
BIO-SPECIMEN
Guiding principle
1. Sharing data and biological samples (bio-resources) is essential for
accelerating biomedical research projects that will provide benefits to
current and future patients.
Research conducted through biobanks and registries is more
effective if access to sufficient data is granted, and the use of data is
maximized through data sharing. Ensuring secure data and sample
sharing ethically and legally protects bio-resources, as well as the
donors and all the partners involved in research.
Sharing data and bio-specimens
2. DTA/(MTA: DTAs and MTAs should always be used to govern
data/material transfer between parties.
DTAs and MTAs are legal contracts that help ensure that the parties
signing the agreement will comply with a set of rules defined by the
involved parties. These documents state the scope of the use of data or
bio-specimens, the limits posed by the informed consent used for the
original collection, special limitations, duration of sharing and use,
and other special conditions including donors’ expectations, etc.
Security and privacy regulations
3. Data and bio-specimens shall always be collected, stored and
exchanged in a secure manner, through secure channels. Double
coding and encryption are highly recommended for data handling.
The type of data and bio-specimens provided to researchers should be
described clearly in the DTA or MTA.
4. Data sharing should only occur when proper ethics review board
approvals are in place (approval for the collection of the materials and
approval for the single research projects).
5. Anonymization of data and bio-resources should generally be
avoided because it will make it impossible to add individual-level data
as science progresses, and precludes re-contacting donors to commu-
nicate future medical discoveries that may benefit them.
6. Donors should be informed that the confidentiality of their
information will be protected through secure technology and strict
coding measures, but that there is no guarantee of complete
confidentiality because of the evolving variety of techniques and
technology advances in genome and gene sequencing that may lead
to the potential identification of the individual.
7. Sharing occurring in international contexts should ensure that
fundamental privacy interests are respected. The processing of
personal data abroad requires authorization from a data inspection
authority or by duly authorized institutional review board (IRB) unless
directly permitted by law (general authorizations).
The European Medicines Agency has recommended a strict
nomenclature, which we have adapted here with regard to both bio-
specimen and data (Hansson31):
 Identified data and bio-specimens: data labelled or linked to the
individual in a way that makes them directly identifiable (name and
surname or social security numbers).
 Coded data (may be single or double coded): personally identifying
information is removed from data and bio-specimens and replaced
with a code. In the case of double-coding, two or more codes are
assigned to the same donor’s data held in different data sets, with
the key connecting the codes back to the donor’s direct identifiers
held by a third party and not available to the researchers.
 Anonymized data and bio-specimens: data and samples that have
been identified earlier or coded, but the identification, or the code
and the code key have been destroyed, and thus there is no longer
any link to the individual.
 Anonymous data and bio-specimens: there are no links to the
individual donor, the data and bio-specimens were never associated
with identifiers, and the risk of identification of individuals is very
low. There may be general descriptions such as ‘man, aged 50–55
years, cholesterol level 240mg per 100ml.’
For all above-mentioned categories, it is assumed that international
and national regulations on access, informed consent, coding and data
protection apply.
Health-related personal data are classified as sensitive, implying that
data protection and confidentiality laws apply and that processing
requires consent from the data subject or legal permission. Data
sharing of personal data is a form of data ‘processing’, in accordance
with National and International Regulation such as the EU directive
95/46/EC on personal data protection or in the US, HHS Regulations
for the Protection of Human Subjects (http://www.hhs.gov/ohrp/
humansubjects/guidance/45cfr46.html#46.102) and the Health
Insurance Portability and Accountability Act (HIPAA) Privacy Rule,
45 CFR 164.514(b).2
Ensuring the scientific use of data and bio-specimens
8. Without distinction, access and use of data and samples should
always be based on the scientific validity, quality and potential of the
request. Those who contribute, collect, curate and annotate samples/
data, however, should have first rights to publish within a given time
period (usually no longer than 1 year).
9. In addition, the identity and bona fide of the requestors should be
authenticated. Proper attribution and intellectual property should be
accorded as appropriate, and the security of the data and samples
should always be ensured.
Charter of principles for international sharing
D Mascalzoni et al
724
European Journal of Human Genetics
In recognition of the contribution of the samples and data of
patients, research participants and their families, the protocols of those
requesting access for use should be vetted for their scientific validity
and quality.
Acknowledgment of the bio-resources and data providers
10. The sharing of data and bio-specimens should follow criteria for
the acknowledgement of intellectual contributions and originality
through rules of authorship and intellectual property rights.
Many consider data collections and genomic databases a public
good contributing to the improvement of public health, often serving
as an incentive for governmental spending. This in itself will motivate
the sharing of data and bio-specimens. However, it does not exclude
the recognition of the interests of the researchers who have invested a
great deal of intellectual effort in establishing the databases, registries
and bio-specimen collections. An analogous example is the publication
of scientific results, which can also be seen as instrumental to public
health. However, unlike the sharing of data and bio-specimens,
the dissemination of research results is associated with established
criteria for the acknowledgement of intellectual contributions
and originality through rules of authorship and intellectual property
rights. We suggest five categories that should reflect different ladders
of merit and following levels of recognition as proposed in the
table below:
 Data included in official governmental administrative databases
These sets of data should be available for research. As they are
created for public interest they should not lead to authorship or
special recognition.
 Data from health quality registries organized by researchers/
clinicians
These registries are normally organized within the national health-
care systems and should in principle be publicly available for
research. However, there is often a dedicated group of doctors/
researchers who invest intellectual as well as material resources in
collecting and systematizing data. This should be recognized in the
acknowledgements of an article that builds on the collected data
but not lead to authorship. There may be a fee-for-service for
providing access to the data.
 Descriptive data directly accessible through health records or
available instruments
These data should in principle be openly available with due
reference to the original source of the instrument. Some instru-
ments are also made publicly available for a fee.
 Hypothesis-generated data and bio-specimens collection available
after screening or within a specific project, or processed data
Should in principle be available, but the principal investigator (PI)
and researchers in the project should have time to explore and
confirm preliminary findings. There may be a fee for service for
providing access to the data. Normally, the conditions for the
sharing of data should be part of the original agreement with the
funder and be subject to the review process of the scientific
journals. Requests for data and bio-specimens could include an
offer of co-authorship to the PI when significant contribution to
the acquisition, analysis or interpretation of data is made and
acknowledgements to the consortium or the biobank.
 Processed data: for example, GWAS data, omics data, whole-
genome sequence data
The processing of bio-specimens to obtain data is a considerable
investment by the institution and reflects a significant contribution
to the acquisition, analysis and interpretation of data. Therefore,
requests for data and bio-specimens could include an offer of
co-authorship to the PI or the consortium and a note in the
acknowledgements.
 Acknowledgement for biobanks/data providers
Biobanks are infrastructure created with the purpose of providing
data and bio-specimens for research purposes. Authorship may not
be a proper recognition mean. A recommended way to recognize
the role of the data/bio-specimen provider is through the emerging
bio-resource research impact factor (BRIF). As described by P3G,
BRIF is ‘a tool to calculate the research impact of bio-resources
based on a unique digital resource identifier and on a metrics
algorithm somewhat analogous to the journal impact factor.’
Further information on BRIF can be found on the P3G website
at http://www.p3g.org/brif-bioshare-pilot-study.
The kind of acknowledgment foreseen for the use of bio-resources
and data should be clearly defined. For all categories, it is assumed that
European and national regulations on access, informed consent,
coding and data protection apply.
It is recommended in appropriate cases that when data from a
common database is analysed, the results should be fed back to the
common database. In order to recognize intellectual contributions, the
researcher/research group who carried out the analyses should be
entitled to a period of exclusivity of use of the results in order to
explore their potential. Following the tradition of a ‘grace period’ in
association with balancing publication interests versus investigating
patentability, 6 months to 1 year of such exclusive use should be
usually granted.
Quality of data and bio-specimens
11. Quality of data and bio-specimens must be ensured by the
provider.
The quality of data and bio-specimens must be ensured in
accordance with international standards. The integration of data
across research groups and national borders implies that data must
be sufficiently equivalent. As suggested by the DataSHaPER platform
for harmonizing data collection in epidemiological research, the level
of equivalence with regard to primary information collected (eg,
serum cholesterol level) and qualifying factors that may affect the
interpretation of data (eg, whether the subject had been fasting before
measurement) is likely to be context- or consortium specific. Accord-
ingly, issues concerning the quality of data have to be sorted out
separately by each consortium before sharing.
Informed consent
12. Informed consent: informed consent to the general scope of the
research project is mandatory. If broad consent is used, regular
updates on the development and the aggregated results of the
project/biobank are recommended, as they serve as reminders of
on-going participation and keep the participants involved. Informed
consent should also offer the clear option for the participant to
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withdraw from the research. Ongoing ethics oversight by proper
review or ethics review boards is recommended.
At the time of data and sample collection, future research use may
be difficult to anticipate or may only be describable in very broad
general terms, for example, for ‘cancer research’, ‘rare disease research’
or ‘medical research’. Therefore, broad consent with ethics approval,
with the right to withdraw from the study, is acceptable if there is a
continuous flow of information on project developments. We there-
fore suggest that templates for informed consent in research projects
of an epidemiological character may be based on broad consent if they
are supported by a commitment by the PI/project to provide regular
updates in a timely and sufficiently comprehensive manner. Informa-
tion especially relevant for data sharing should be disclosed in the
information sheets.
In the information provided, it should be clearly specified whether
or not:
 the research project reasonably anticipates the sharing of data across
research groups and national borders.
 complementary information may be added through linkage to
different data registries, medical records, etc.
 the project involves genetic analyses.
 the project involves collaboration with both academic and com-
mercial partners.
Participants should be allowed to have some options to express
choices, or at least be provided clear information on the policy for
return of incidental findings, the destination of data and bio-
specimens after death or in the case of the termination of the project,
and the involvement of relatives in research. A description of the
communication of information strategy flowing from the project
should be provided, and should include the general development of
project timelines and newsletters or website updates dedicated to the
donors.
Use of previously collected data and samples
13. For the use of previously collected data and bio-specimen where
consent is absent or not fit for purpose, we recommend a case by case
assessment by an ethics board. According to national legal require-
ments, either re-consent or a notification with opt-out schemes should
be required in order to enable the institution to use and share
internationally. This is especially important where minors (at the time
of the collection) are involved. In some cases – where re-contact of
patients is unfeasible and disproportionate to benefits (very old
collections) – a waiver for re-consent can be granted by an ethics
review board (please refer to national legal requirements). In this case,
a clear outline of the reasons for requiring the waiver should be
provided to the ethics board. A clear distinction should be made
between collections in which a previous consent was obtained and
where a question was not asked – and – one where a patient actively
declined some options, for which re-consent is required.
Return of results to sharing partner institutions
14. Any agreement on sharing should regulate:
 Return of results significant for individuals that provided the bio-
materials (the source institution remains responsible for that).
 Return of aggregated or other types of results to the source biobank/
database.
Results from research may have a specific value for public health
and individual health. Custodianship implies recognizing the role of
research institutions and their legal and ethical duties to participants
and patients. There is also agreement that aggregated research results
should be disseminated to institutions and patients; regardless of the
kind of policy of return of results adopted, these should be made
explicit. Short reports should be provided by the research team to the
data providers (institutions, biobanks) in order to ensure awareness of
results relevant to their collections or to the donors. These reports may
contain a publication list and relevant results important for further
research developments or directly relevant to donors.
Intellectual property
15. The sharing of data and bio-resources must be done in a way that
protects proprietary information and addresses the interests of
institutions and third-party funders. These parties may have legitimate
proprietary interests associated with data collected by researchers.
The intellectual investment of investigators involved in the creation
and maintenance of data registries and bio-repositories is often
substantial, and should be appropriately acknowledged.
MTA/DTA TEMPLATE
Mutual agreement between provider and recipient
Provider of data…………………………………………..
Recipient of data……………………………………….. (This must
be an institution officially registered by national/regional authorities.)
MTA/DTA must be signed before any exchange takes place
1. Provider. Provider………………………………….. hereby
declares that:
The (name country) …………….. from which the human biolo-
gical material is collected has a legal and ethical framework providing a
high level of quality, security and privacy protection concerning
medical research involving human biological material; and that health
data exchange is in accordance with local regulation (please note that
some regulations, such as those from the EU, require compliance with
their rules even if the research is conducted abroad).
Data/bio-specimens provided consist of the following:
…………………………………….. (description including type of
material and type of data: primary data and which type, genotypes,
aggregate data, etc.)
The bio-specimens provided refer to…. (no. of individuals) and are
composed of ….. (no. of tubes and quantity of material referred to the
scope).
The material will be de-identified, stripped of all personally
identifying information, without any direct means of identification.
Bio-specimens will be double-coded (no direct identifier shall be on
the tubes).
To ensure the confidentiality and security of the associated data,
transfer and processing will be handled safely and associated data will
not be transported together with bio-specimens.
To ensure traceability of the material to be de-identified, a code will
be applied to the tubes. The mechanism to re-identify the data will
remain with the provider.
To ensure exchange and transport security, biosafety (packaging,
labelling description of transport means and insurance for bio-
specimens) will be observed.
The project from which the data and bio-specimens were collected
was approved by a local ethics committee or IRB.
Informed consent for storage and distribution was obtained
(enclose a copy of the model in use), and that:
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 the informed consent contained the clause necessary for allowing
bio-specimens and data sharing abroad (in case of an international
project).
 the informed consent allowed the research described in the project
description section.
2. Recipient. Recipient………………………………….. hereby
declares that:
 the data will be used solely for the scope of the project described
below, and no attempt will be made to sell the data/material or
share it with a third party. The data/samples will be used for the
following purpose: (description of the biomedical research
project of the Recipient (or of the joint project):
………………………………….(aims should be clear, including
the duration of the project………………………….
 authorization from the local ethics review committee or IRB
………………………(date and copy enclosed).
 when consented to, will ensure the return of results relevant to the
health of individuals …………….. and ……………………
………………………………….(description of the type of data
that must be returned).
 will not harm the persons who provided bio-specimens by naming
the provenience of the bio-specimens unless approved by the
Provider.
3. Terms and conditions (for Recipient). Conditions of use include:
 no attempt to re-identify the participants
 adherence to use limitations stated in approved application
 no third-party data or sample sharing/selling without authorization
from Provider
 primary data must not be patented
 that the use of the material has, for example, medical/public health
objectives
 informing the resource of issues related to data integrity and/or the
privacy of the participants as applicable
 compliance with original consents and applicable laws and institu-
tional policies
 access granted for a limited time period (eg, 6 months or
……………), after which Recipient must reapply.
Documents to be provided by the recipient institution:
1. Authorization from a local ethics committee or a regional or local
competent authority for the project for which the data are provided
(by Recipient or, in the case of a joint project, by both parties).
2. Documents by the national data protection authority that reference
the applicable laws that allow research using sensitive and health
data, including genetic data.
4. Receipt and handling of imported biological material. The Recipient
must document and follow the procedures for the receipt and proper
storage of the type of biological material handled.
Provider has to prepare and ship the biological material in
accordance with postal regulations, such as IATA (International
Air Transport Association) and ADR (European Agreement on
International Carriage of Dangerous Goods).
5. Publication. Prior review of publications before submission may be
required (eg, to ensure the privacy/confidentiality of data and that the
results will not cause stigmatization). Recipients should acknowledge the
biobank/data provider in any publication/presentation (or other clauses).
6. Is the material used to be returned or destroyed? Recipient will
comply with the destruction/return of unused bio-specimens and of
data related to the bio-specimens at the end of the project or of the
duration stated above
Description of the requirement (destruction/return)…………
……………………………………..
7. Intellectual property rights. (Requires a specific agreement
case by case. See general Introduction)………………………
………………………………………………………………………
……..
8. Who controls the data/bio-specimens in the resource? Control of the
bio-specimens remains with Provider, who can at any time demand
the return or destruction of data and bio-specimens if a breach in the
agreement occurs.
9. Obligation to report. Annual…………… (or other) and
final reports to Provider are required. Reports should include
………………………………………………………………………
(specify required content).
10. Responsibilities of the biobank/consortia. Biobanks and research
consortia have the right to terminate/alter this agreement with the
researcher/institution, for the safety of the patients/participants or
because of any infringements of the obligations stated in the present
DTA/MTA. The Recipient understands and agrees that Provider does
not bear any responsibility or accept any liability arising from the
Recipient’s use of the data or bio-specimens.
Time, place and signatures of the persons legally responsible for the
institutions involved.
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